Finerenone as adjunctive therapy for residual proteinuria in lupus nephritis: a case series of 10 patients - Takeaways - MDSpire

Finerenone as adjunctive therapy for residual proteinuria in lupus nephritis: a case series of 10 patients

Share

1

Finerenone was added to the treatment of 10 lupus nephritis patients with residual proteinuria after standard therapy for at least 6 months.
2

The study observed a significant reduction in 24-hour urine protein quantification from 1.595 g at baseline to 0.315 g at 24 weeks.
3

Serum albumin levels increased from 3.68 g/dL at baseline to 4.075 g/dL at 24 weeks, indicating improved protein status.
4

Estimated glomerular filtration rate (eGFR) remained stable throughout the 24-week follow-up period.
5

All patients completed the study, and finerenone was associated with favorable safety outcomes in this cohort.